Abstract

Emerging evidence is revealing that alterations in gut microbiota are associated with colorectal cancer (CRC). However, very little is currently known about whether and how gut microbiota alterations are causally associated with CRC development. Here we show that 12 faecal bacterial taxa are enriched in CRC patients in two independent cohort studies. Among them, 2 Porphyromonas species are capable of inducing cellular senescence, an oncogenic stress response, through the secretion of the bacterial metabolite, butyrate. Notably, the invasion of these bacteria is observed in the CRC tissues, coinciding with the elevation of butyrate levels and signs of senescence-associated inflammatory phenotypes. Moreover, although the administration of these bacteria into ApcΔ14/+ mice accelerate the onset of colorectal tumours, this is not the case when bacterial butyrate-synthesis genes are disrupted. These results suggest a causal relationship between Porphyromonas species overgrowth and colorectal tumourigenesis which may be due to butyrate-induced senescence.

Several bacteria in the gut microbiota have been associated with colorectal cancer (CRC) but it is not completely clear whether they have a role in tumourigenesis. Here, the authors show enrichment of 12 bacterial taxa in two cohorts of CRC patients and that two Porphyromonas species accelerate CRC onset through butyrate secretion.

Details

Title
Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion
Author
Okumura Shintaro 1   VIAFID ORCID Logo  ; Konishi Yusuke 2 ; Narukawa Megumi 2 ; Sugiura Yuki 3 ; Yoshimoto Shin 4 ; Arai Yuriko 5 ; Sato Shintaro 2 ; Yoshida Yasuo 6 ; Tsuji Shunya 2 ; Uemura, Ken 2 ; Wakita Masahiro 7 ; Matsudaira Tatsuyuki 2 ; Matsumoto Tomonori 2 ; Kawamoto Shimpei 2 ; Takahashi, Akiko 5   VIAFID ORCID Logo  ; Itatani Yoshiro 8   VIAFID ORCID Logo  ; Miki Hiroaki 2   VIAFID ORCID Logo  ; Takamatsu Manabu 9 ; Obama Kazutaka 8 ; Takeuchi Kengo 10   VIAFID ORCID Logo  ; Suematsu Makoto 3   VIAFID ORCID Logo  ; Ohtani Naoko 11   VIAFID ORCID Logo  ; Fukunaga Yosuke 9   VIAFID ORCID Logo  ; Ueno Masashi 9 ; Sakai Yoshiharu 8 ; Nagayama Satoshi 9   VIAFID ORCID Logo  ; Hara Eiji 12   VIAFID ORCID Logo 

 Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Graduate School of Medicine, Kyoto University, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033) 
 Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971) 
 Keio University School of Medicine, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959) 
 The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); LSI Medience Corporation, Tokyo, Japan (GRID:grid.410807.a) 
 The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131) 
 School of Dentistry, Aichi Gakuin University, Nagoya, Japan (GRID:grid.411253.0) (ISNI:0000 0001 2189 9594) 
 Immunology Frontier Research Centre (IFReC), Osaka University, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971) 
 Graduate School of Medicine, Kyoto University, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033) 
 The Cancer Institute Hospital, JFCR, Tokyo, Japan (GRID:grid.486756.e) (ISNI:0000 0004 0443 165X) 
10  The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); The Cancer Institute Hospital, JFCR, Tokyo, Japan (GRID:grid.486756.e) (ISNI:0000 0004 0443 165X) 
11  Osaka City University Graduate School of Medicine, Osaka, Japan (GRID:grid.261445.0) (ISNI:0000 0001 1009 6411) 
12  Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971); The Cancer Institute, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan (GRID:grid.410807.a) (ISNI:0000 0001 0037 4131); Immunology Frontier Research Centre (IFReC), Osaka University, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2576851017
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.